DaviesPBDrummMKonstanMW. Cystic fibrosis. Am J Respir Crit Care Med. 1996;154:1229-1256.
4.
CoreyMMcLaughlinFJWilliamsM. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol. 1988;41:583-591.
5.
Cystic Fibrosis Foundation patient data registry. Bethesda, MD: Cystic Fibrosis Foundation; 2009.
6.
KonstanMWButlerSMWohlMEB. Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. J Pediatr. 2003;142:624-630.
7.
LittlewoodJMWolfeSPConwaySP. Diagnosis and treatment of intestinal malabsorption in cystic fibrosis. Pediatr Pulmonol. 2006;41:35-49.
8.
RobinsonPJSmithALSlyPD. Duodenal pH in cystic fibrosis and its relationship to fat malabsorption. Dig Dis Sci. 1990;35: 1299-1304.
9.
BellSCBowermanAMNixonLEMacdonaldIAElbornJSShaleDJ. Metabolic and inflammatory responses to pulmonary exacerbation in adults with cystic fibrosis. Eur J Clin Invest. 2000;30:553-559.
10.
DorlöchterLRøksundOHelgheimVRosendahlKFlugeG. Resting energy expenditure and lung disease in cystic fibrosis. J Cyst Fibros. 2002;1:131-136.
11.
GirardetJPTounianPSardetA. Resting energy expenditure in infants with cystic fibrosis. J Pediatr Gastroenterol Nutr. 1994;18:214-219.
12.
ThomsonMAWilmottRWWainwrightCMastersBFrancisPJShepherdRW. Resting energy expenditure, pulmonary inflammation, and genotype in the early course of cystic fibrosis. J Pediatr. 1996;129:367-373.
13.
FeigalRJShapiroBL. Mitochondrial calcium uptake and oxygen consumption in cystic fibrosis. Nature. 1979;278:276-277.
14.
BronsteinMNDaviesPSHambidgeKMAccursoFJ. Normal energy expenditure in the infant with presymptomatic cystic fibrosis. J Pediatr. 1995;126:28-33.
15.
BinesJETrubyHDArmstrongDSPhelanPDGrimwoodK. Energy metabolism in infants with cystic fibrosis. J Pediatr. 2002;140:527-533.
16.
FriedMDDuriePRTsuiLCCoreyMLevisonHPencharzPB. The cystic fibrosis gene and resting energy expenditure. J Pediatr. 1991;119:913-916.
17.
KalivianakisMMinichDMBijleveldCMAvan AalderenWMCStellaardFLaseurM. Fat malabsorption in cystic fibrosis patients receiving enzyme replacement therapy is due to impaired intestinal uptake of long-chain fatty acids. Am J Clin Nutr. 1999:69:127-134.
18.
BorowitzDRobinsonKRosenfeldM. Cystic fibrosis foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr. 2009; 155:S73-93.
19.
BorowitzDBakerRDStallingsV. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2002;35:246-259.
20.
Subcommittee on the Tenth Edition of the RDAs, Food and Nutrition Board, Commission on Life Sciences, National Research Council. Recommended Dietary Allowances. 10th ed.Washington, DC; National Academy Press; 1989.
21.
MaqboolAStallingsVA. Update on fat-soluble vitamins in cystic fibrosis. Curr Opin Pulm Med. 2008;14:574-581.
22.
MaqboolAGraham-MaarRCSchallJL. Vitamin A intake and elevated serum retinol levels in children and young adults with cystic fibrosis. Am J Clin Nutr. 2008;7:137-141.
23.
HolickMF. The vitamin D epidemic and its health consequences. J Nutr. 2005;135:2739S-2748S.
24.
LookerACDawson-HughesBCalvoMS. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone. 2002;30:771-777.
25.
RovnerAJO’BrienKO. Hypovitaminosis D among healthy children in the United States: a review of the current evidence. Arch Pediatr Adolesc Med. 2008;162:513-519.
26.
StephensonABrotherwoodMRobertR. Cholecalciferol significantly increases 25-hydroxyvitamin D concentrations in adults with cystic fibrosis. Am J Clin Nutr. 2007;85:1307-1311.
27.
RovnerAJStallingsVASchallJL. Vitamin D insufficiency in children, adolescents, and young adults with cystic fibrosis despite routine oral supplementation. Am J Clin Nutr. 2007;86:1694-1699.
28.
HaworthCSSelbyPLWebbAK. Low bone mineral density in adults with cystic fibrosis. Thorax. 1999;54:961-967.
29.
ArisRMMerkelPABachrachLK. Consensus statement: guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab. 2005;90:1888-1896.
30.
BoyleMPNoscheseMLWattsSL. Failure of high-dose ergocalciferol to correct vitamin D deficiency in adults with cystic fibrosis. Am J Respir Crit Care Med. 2005;172:212-217.
31.
ArmasLAHollisBWHeaneyRP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 2004;89:5387-5391.
32.
TrangHMColeDERubinLA. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr. 1998;68:854-858.
33.
KhazaiNBJuddSEJengL. Treatment and prevention of vitamin D insufficiency in cystic fibrosis patients: comparative efficacy of ergocalciferol, cholecalciferol and UV light. J Clin Endocrinol Metab. 2009;94:2037-2043.
34.
GreenDMLeonardARParanjapeSM. Transient effectiveness of vitamin D2 therapy in pediatric cystic fibrosis patients. J Cyst Fibros. 2010;9:143-149.
35.
SatheMNPatelAS. Update in pediatrics: focus on fat-soluble vitamins. Nutr Clin Pract. 2010;25:340-346.
36.
BoasSRHagemanJRHoLTLiverisM. Very high-dose ergocalciferol is effective for correcting vitamin D deficiency in children and young adults with cystic fibrosis. J Cyst Fibros. 2009;8: 270-272.
37.
CarrSBMcBratneyJ. The role of vitamins in cystic fibrosis. J R Soc Med. 2000;93(suppl 38):14-19.
38.
WilfondBSFarrellPMLaxovaA. Severe hemolytic anemia associated with vitamin E deficiency in infants with cystic fibrosis: implications for neonatal screening. Clin Pediatr. 1994; 33:2-7.
39.
WillisonHGMullerDPRMatthewsS. A study of the relationship between neurological function and serum vitamin E concentrations in patients with cystic fibrosis. J Neurol Neurosurg Psychiatry. 1985;48:1097-1102.
40.
SitrinMDLiebermanFJensenWE. Vitamin E deficiency and neurologic disease in adults with cystic fibrosis. Ann Intern Med. 1987;107:51-54.
41.
CynamonHAMilovDEValensteinEWagnerM. Effect of vitamin E deficiency on neurologic function in patients with cystic fibrosis. J Pediatr. 1988;113:637-640.
42.
HorwittMKHarveyCCDahmCHJrSearcyMT. Relationship between tocopherol and serum lipid levels for determination of nutritional adequacy. Ann N Y Acad Sci. 1972;203:223-236.
43.
ThurnhamDIDaviesJACrumpBJ. The use of different lipids to express serum tocopherol: lipid ratios for the measurement of vitamin E status. Ann Clin Biochem. 1986;23(pt 5):514-20.
44.
JamesDRAlfahamMGoodchildMC. Increased susceptibility to peroxide-induced haemolysis with normal vitamin E concentrations in cystic fibrosis. Clin Chim Acta. 1991;204:279-290.
45.
MottaMEFAStarlingALPPennaFJ. Nutritional care in childhood cholestasis. Int Pediatr. 1999;14:213-220.
46.
RamaccioniVSorianoHEArumugumR. Nutritional aspects of chronic liver disease and liver transplantation in children. J Pediatr Gastroenterol Nutr. 2000;30:361-367.
47.
DuriePR. Vitamin K and the management of patients with cystic fibrosis. CMAJ. 1994;151:933-936.
48.
DoughertyKASchallJIStallingsVA. Suboptimal vitamin K status despite supplementation in children and young adults with cystic fibrosis. Am J Clin Nutr. 2010;92:660-667.
49.
SchwarzenbergSJWielinskiCLShamiehBLM. Cystic fibrois-associated colitis and fibrosing colonopathy. J Pediatr. 1995;127:565-570.
50.
AnelliMForestiRPelosoLOrtenziG. Overfilling in current pancreatic enzyme preparations (PEPs): still an unresolved issue. Pediatr Pulmonol. 2007;42:391.
51.
CaseCLHennigesFBarkinJS. Enzyme content and acid stability of enteric coated pancreatic enzyme products in vitro. Pancreas. 2005;30:180-183.
52.
WaltersMPLittlewoodJM. Pancreatin preparations used in the treatment of cystic fibrosis-lipase content and in vitro release. Aliment Pharmacol Ther. 1996;10:433-440.
LittlewoodJMWolfeSPConwaySP. Diagnosis and treatment of intestinal malabsorption in cystic fibrosis. Pediatr Pulmonol. 2006;41:35-49.
55.
ButtAMIpWEllisL. The fate of ingested enzymes in cystic fibrosis. Pediatr Pulmonol. 2001;22(suppl):137-138.
56.
NgSMJonesAP. Drug therapies for reducing gastric acidity in people with cystic fibrosis. Cochrane Database Syst Rev. 2003;2: CD003424.
57.
FranciscoMPWagnerMHShermanJM. Ranitidine and omeprazole as adjuvant therapy to pancrelipase to improve fat absorption in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2002;35:79-83.
58.
ErskineJMLingardCDSontagMK. Enteral nutrition for patients with cystic fibrosis: comparison of a semi-elemental and nonelemental formula. J Pediatr. 1998;132:265-269.
WilliamsSGJAshworthFMcAlweenieAPooleSHodsonMEWestabyD. Percutaneous endoscopic gastrostomy feeding in patients with cystic fibrosis. Gut. 1999;44:87-90.
61.
EfratiOMei-ZahavMRivlinJ. Long term nutritional rehabilitation by gastrostomy in Israeli patients with cystic fibrosis: clinical outcome in advanced pulmonary disease. J Pediatr Gastroenterol Nutr. 2006;42:222-228.
62.
Van BiervlietSDeWaeleKVan WinckelMRobberechtE. Percutaneous endoscopic gastrostomy in cystic fibrosis: patient acceptance and effect of overnight tube feeding on nutritional status. Acta Gastroenterol Belg. 2004;67:241-244.
63.
OliverMRHeineRGNgCHVoldersEOlinskyA. Factors affecting clinical outcome in gastrostomy-fed children with cystic fibrosis. Pediatr Pulmonol. 2004;37:324-329.
